(Reuters) -Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its …
therapeutics
-
-
(Reuters) – Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies …
-
By Carolina Mandl NEW YORK (Reuters) – Soros Fund Management, the family office of billionaire George Soros, added to its portfolio new shares in financial and healthcare companies and a …
-
By Sriparna Roy and Khushi Mandowara (Reuters) – TG Therapeutics Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms …
-
Objective: to clinically validate efficacy of a new form of immunotherapy utilizing CAR-T cells to target multiple difficult-to-treat tumors PARIS, June 13, 2022 — Mnemo Therapeutics, a biotechnology company developing …
-
Global biopharmaceutical leader relocating to premier New Jersey campus owned by Rubenstein Partners and Vision Real Estate Partners WARREN, N.J., June 10, 2022 — Rubenstein Partners, L.P. (including its affiliates, Rubenstein), …
-
“In the past year, Cytovia has graduated into a fully-integrated global biotech with R&D and cell manufacturing capabilities. As we advance our product candidates towards clinical trials and prepare to become …
-
BEDMINSTER, N.J., 3 juin 2022 — Jubilant Therapeutics Inc., une société de thérapies de précision au stade clinique qui fait progresser les petites molécules thérapeutiques pour répondre à des besoins …
-
BEDMINSTER, N.J., 3 juin 2022 — Jubilant Therapeutics Inc., une société de thérapies de précision au stade clinique qui fait progresser les petites molécules thérapeutiques pour répondre à des besoins …
-
BEDMINSTER, N.J., 3. Juni 2022 — Jubilant Therapeutics Inc., ein Unternehmen für Präzisionstherapeutika in der klinischen Phase, das niedermolekulare Therapeutika für ungedeckten medizinischen Bedarf in der Onkologie und bei Autoimmunerkrankungen …
-
(Reuters) -The U.S. Food and Drug Administration said on Wednesday it has withdrawn its approval for TG Therapeutics Inc’s lymphatic cancer treatment Ukoniq over concerns of higher risk of death …
-
Le JBI-802 est le premier inhibiteur équipotent double de LSD1 et HDAC6, administré par voie orale Le JBI-802 a démontré une activité anti-tumorale synergique dans les modèles animaux BEDMINSTER, N.J., …
-
JBI-802 ist der erste oral verabreichte, duale äquipotente Hemmstoff von LSD1 und HDAC6 JBI-802 zeigte synergistische Anti-Tumor-Aktivität in Tiermodellen BEDMINSTER, N.J., 27. April 2022 — Jubilant Therapeutics Inc., ein biopharmazeutisches …